Navigation Links
Cephalon Reports Another Strong Quarter
Date:10/28/2008

tax adjustments primarily related to changes in valuation allowances, the settlement of the investigations by the U.S. Attorney's Office and other changes in tax assets and liabilities. The 2008 amount includes $84.5 million of tax benefits for the settlement with the U.S. Attorney's Office, for which the related expense was recorded in 2007 and for the states of Connecticut and Massachusetts, for which the related expense was recorded in the third quarter of 2008.

CEPHALON, INC. AND SUBSIDIARIES

Reconciliation of GAAP Net Income to Adjusted Net Income

(Unaudited)

Nine Months Ended

September 30,

2008 2007

GAAP NET (LOSS) INCOME $210,962 $(235,886)

Cost of sales adjustments 111,349 (1) 64,236 (1)

Research and development adjustments 8,013 (2) 41,500 (2)

Selling, general and administrative

adjustments 30,124 (3) -

Settlement reserve 7,450 (4) 425,000 (4)

Gain on sale of investment - (5,791) (5)

Gain on extinguishment of debt - (5,319) (6)

Interest expense adjustment 11,250 (7)

Restructuring charges 6,973 (8)

In-process research and development 10,000 (9)

Income tax adjustment (143,162) (10) (40,459) (10)

41,997 479,167

ADJUSTED NET INCOME $252,959 $243,281

BASIC ADJUSTED INCOME PER COMMON

SHARE $3.73 $3.66

DILUTED ADJUSTED INCOME PER COMMON

SHARE
'/>"/>

SOURCE Cephalon, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19

Related biology technology :

1. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
2. Cephalon, Inc. Announces Agreement to Acquire AMRIX, A Once-Daily Extended-Release Muscle Relaxant
3. Cephalon Reinforces Important Prescribing and Dosing Information for FENTORA
4. Cephalon Submits New Drug Application for TREANDA for the Treatment of Chronic Lymphocytic Leukemia
5. Cephalon Quarterly Conference Call Invitation
6. Cephalon Announces Strong Third Quarter Financial Results
7. Cephalon Submits Supplemental New Drug Application for FENTORA
8. Cephalon Submits New Drug Application for TREANDA for the Treatment of Patients with Relapsed Indolent Non-Hodgkins Lymphoma
9. Cephalon Presentation Slides for the 26th Annual JPMorgan Healthcare Conference Now Available
10. Cephalons EFFENTORA Receives Positive Opinion from European Regulatory Authorities for the Management of Breakthrough Cancer Pain
11. Cephalon Provides Update on Regulatory Status of the FENTORA Supplemental New Drug Application
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)... (PRWEB) November 21, 2014 Why did ... makes Albert Einstein so instantly recognizable? Why have they ... mathematician, astronomer and author Hilton Ratcliffe seeks out the ... nothing at all to do with science. In " ... Publishing , November 21, 2014), Ratcliffe puts it plainly: ...
(Date:11/21/2014)... DIEGO , Nov. 20, 2014  Cytori Therapeutics (NASDAQ: ... Marc Hedrick , M.D. will present live at VirtualInvestorConferences.com on ... 2014 TIME:    11:15 am PT / 2:15 pm ... URL into your browser,s address bar: http://bit.ly/1B2KGaL ... and receive event updates. This will be ...
(Date:11/18/2014)... 17, 2014 pH measurement and control ... the pharmaceutical, chemical, and food and beverage industries. But ... and how do pH sensors work? METTLER TOLEDO has ... in process industries with these questions and more. , ... in the process industries. The actual sensor, the pH ...
(Date:11/18/2014)... Texas (PRWEB) November 18, 2014 ... Polytetrahydrofuran (PTMEG) Industry is professional and in-depth ... gives Polytetrahydrofuran basic information, including its definition, ... also industry outline. This exploration covers the ... and worldwide industry examination covering macroeconomic environment ...
Breaking Biology Technology:“Stephen Hawking Smoked My Socks” Sparks Controversy in Science World 2“Stephen Hawking Smoked My Socks” Sparks Controversy in Science World 3“Stephen Hawking Smoked My Socks” Sparks Controversy in Science World 4Cytori Therapeutics to Provide Corporate Update and Investor Presentation on December 4 through a Live, Interactive Webcast 2Cytori Therapeutics to Provide Corporate Update and Investor Presentation on December 4 through a Live, Interactive Webcast 3Cytori Therapeutics to Provide Corporate Update and Investor Presentation on December 4 through a Live, Interactive Webcast 4pH Guide from METTLER TOLEDO Explains Measurement, Theory and Practice of pH Applications 2PTMEG Market: 2019 Global Polytetrahydrofuran Industry Development Trends & Analysis Now at DeepResearchReports.com 2PTMEG Market: 2019 Global Polytetrahydrofuran Industry Development Trends & Analysis Now at DeepResearchReports.com 3
... to Glipizide... -- STOCKHOLM, September 24, 2010 ... ... ... Results are keyed by longUrl, so we need to grab the first one. for (var r in ...
... Fla., Sept. 23 GeneLink, Inc. (OTC ... genomics biotech company, is pleased to report that the ... the complaint filed by the Company,s former CEO and ... against the Company, its subsidiary GeneWize Life Sciences, Inc., ...
... biological samples generated during clinical research is rapidly increasing ... from traditional medicine to molecular-based therapeutics. The growing use ... put an increasing emphasis on the value of sample ... to collect, store and distribute clinical trial samples. ...
Cached Biology Technology:52-Week Phase 3 Study Found Investigational Drug Dapagliflozin Plus Metformin Similar to Glipizide Plus Metformin in Improving Glycosylated Hemoglobin (HbA1c) in Adults with Type 2 Diabetes Mellitus 252-Week Phase 3 Study Found Investigational Drug Dapagliflozin Plus Metformin Similar to Glipizide Plus Metformin in Improving Glycosylated Hemoglobin (HbA1c) in Adults with Type 2 Diabetes Mellitus 352-Week Phase 3 Study Found Investigational Drug Dapagliflozin Plus Metformin Similar to Glipizide Plus Metformin in Improving Glycosylated Hemoglobin (HbA1c) in Adults with Type 2 Diabetes Mellitus 452-Week Phase 3 Study Found Investigational Drug Dapagliflozin Plus Metformin Similar to Glipizide Plus Metformin in Improving Glycosylated Hemoglobin (HbA1c) in Adults with Type 2 Diabetes Mellitus 552-Week Phase 3 Study Found Investigational Drug Dapagliflozin Plus Metformin Similar to Glipizide Plus Metformin in Improving Glycosylated Hemoglobin (HbA1c) in Adults with Type 2 Diabetes Mellitus 652-Week Phase 3 Study Found Investigational Drug Dapagliflozin Plus Metformin Similar to Glipizide Plus Metformin in Improving Glycosylated Hemoglobin (HbA1c) in Adults with Type 2 Diabetes Mellitus 752-Week Phase 3 Study Found Investigational Drug Dapagliflozin Plus Metformin Similar to Glipizide Plus Metformin in Improving Glycosylated Hemoglobin (HbA1c) in Adults with Type 2 Diabetes Mellitus 852-Week Phase 3 Study Found Investigational Drug Dapagliflozin Plus Metformin Similar to Glipizide Plus Metformin in Improving Glycosylated Hemoglobin (HbA1c) in Adults with Type 2 Diabetes Mellitus 952-Week Phase 3 Study Found Investigational Drug Dapagliflozin Plus Metformin Similar to Glipizide Plus Metformin in Improving Glycosylated Hemoglobin (HbA1c) in Adults with Type 2 Diabetes Mellitus 1052-Week Phase 3 Study Found Investigational Drug Dapagliflozin Plus Metformin Similar to Glipizide Plus Metformin in Improving Glycosylated Hemoglobin (HbA1c) in Adults with Type 2 Diabetes Mellitus 1152-Week Phase 3 Study Found Investigational Drug Dapagliflozin Plus Metformin Similar to Glipizide Plus Metformin in Improving Glycosylated Hemoglobin (HbA1c) in Adults with Type 2 Diabetes Mellitus 12BioStorage Technologies Brings Together Industry Leaders for Global Sample Management Benchmarking Symposium 2BioStorage Technologies Brings Together Industry Leaders for Global Sample Management Benchmarking Symposium 3
(Date:11/4/2014)... of Medicine announced today that it is a ... the Bill & Melinda Gates Foundation. Laura ... Reproductive Sciences; and Vice Chair of Research and ... will pursue an innovative global health and development ... Fetal Neurodevelopment.", Grand Challenges Explorations (GCE) funds individuals ...
(Date:11/4/2014)... VILNIUS, Lithuania , Nov. 4, 2014 /PRNewswire/ ... identification technologies, today announced that the latest version ... place in the Ongoing MINEX evaluation ... interoperability of fingerprint algorithms using the INCITS 378 ... a mandatory requirement in public tenders in ...
(Date:11/2/2014)... month,s issue of Physics World , James Dacey ... "valley of death" to take their innovations from the ... the gruelling challenge facing all start-up companies as they ... physicists because of two main factors: physics-based inventions are ... often turn out to be a lot more complicated ...
Breaking Biology News(10 mins):Temple University School of Medicine receives Grand Challenges Explorations grant 2Neurotechnology Places Second in Ongoing MINEX Ranking for Fingerprint Matching Algorithms 2Neurotechnology Places Second in Ongoing MINEX Ranking for Fingerprint Matching Algorithms 3The 'valley of death' facing physics start-ups 2
... In what could be a breakthrough in animal breeding, a ... a set of genetic regions responsible for animal tameness. This ... GENETICS ( http://www.genetics.org ), should help animal breeders, ... to more fully understand what makes some animals interact with ...
... jays use over a dozen different calls to communicate ... members of their own group. A Swedish study from ... Royal Society Biological Sciences , shows birds have evolved ... of primates and meerkats. Most prey immediately escape ...
... or muscle wasting that afflicts cancer or AIDS patients, the ... to liberate amino acids. In a new study published online ... of the Journal of Cell Biology ( www.jcb.org ... atrophy is a more ordered process than was previously thought. ...
Cached Biology News:Horse whisperers, lion tamers not needed: Scientists find genetic regions that soothe savage beasts 2Siberian jays use complex communication to mob predators 2Muscle atrophy through thick but not thin 2
... Label IT siRNA Tracker Intracellular Localization Kit ... label and deliver siRNA, of your design, ... in vitro tracking experiments. Subcellular localization and ... be monitored following introduction of the labeled ...
... The Label IT siRNA Tracker Intracellular Localization ... directly label and deliver siRNA, of your ... for in vitro tracking experiments. Subcellular localization ... can be monitored following introduction of the ...
... This CLS number is ... to easily match Cornings product ... yet, please order under the ... contact customer service for assistance. ...
... (ECM) is an important step in tumor ... adhering to and spreading along the blood ... MMP collagenases, dissolve tiny holes in the ... vessels to allow cancer cells to invade.,The ...
Biology Products: